Literature DB >> 10468614

Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.

C Y Wang1, L S Sawyer, K K Murthy, X Fang, A M Walfield, J Ye, J J Wang, P D Chen, M L Li, M T Salas, M Shen, M C Gauduin, R W Boyle, R A Koup, D C Montefiori, J R Mascola, W C Koff, C V Hanson.   

Abstract

mAb B4 is a monoclonal antibody directed against HIV receptor complex. The antibody had broad neutralizing activity against HIV and provided postexposure prophylaxis to hu-peripheral blood leukocyte (PBL)-severe combined immunodeficient mice and chimpanzees. B4 recognized a complex receptor site for HIV on the T cell surface that includes CD4 and also may be influenced by interaction with HIV coreceptors. mAb B4 preferentially neutralized primary HIV-1 isolates compared with T cell line-adapted strains, including syncytium-inducing and non-syncytium-inducing phenotypes, representatives from HIV-1 subtypes A-G, as well as HIV-2, simian immunodeficiency virus, and chimeric simian/human immunodeficiency virus (SHIV). Neutralization was demonstrated in both pre- and postinfection models. The administration of mAb B4 after infectious challenge totally interrupted the infection of hu-PBL-severe combined immunodeficient mice by PBL-grown HIV-1 and the infection of chimpanzees by chimp-adapted HIV-1. This mode of protection suggested that the anti-HIV receptor antibody is efficacious for prophylaxis after exposure to HIV and for prevention of maternal transmission and may be an effective antiretroviral agent for treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468614      PMCID: PMC17894          DOI: 10.1073/pnas.96.18.10367

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5.

Authors:  C K Lapham; M B Zaitseva; S Lee; T Romanstseva; H Golding
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

2.  Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

Authors:  P R Johnson; D C Montefiori; S Goldstein; T E Hamm; J Zhou; S Kitov; N L Haigwood; L Misher; W T London; J L Gerin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

Authors:  J Li; C I Lord; W Haseltine; N L Letvin; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

4.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

5.  Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers.

Authors:  C V Hanson; L Crawford-Miksza; H W Sheppard
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

6.  Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.

Authors:  J R Mascola; M K Louder; S R Surman; T C Vancott; X F Yu; J Bradac; K R Porter; K E Nelson; M Girard; J G McNeil; F E McCutchan; D L Birx; D S Burke
Journal:  AIDS Res Hum Retroviruses       Date:  1996-09-20       Impact factor: 2.205

7.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

Authors:  M C Gauduin; P W Parren; R Weir; C F Barbas; D R Burton; R A Koup
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

8.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

Authors:  T Zhu; H Mo; N Wang; D S Nam; Y Cao; R A Koup; D D Ho
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

9.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

Authors:  J P Moore; Y Cao; J Leu; L Qin; B Korber; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.

Authors:  R Shibata; M D Hoggan; C Broscius; G Englund; T S Theodore; A Buckler-White; L O Arthur; Z Israel; A Schultz; H C Lane
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more
  13 in total

1.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

2.  Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics.

Authors:  Behzad Etemad; Melissa Ghulam-Smith; Oscar Gonzalez; Laura F White; Manish Sagar
Journal:  J Virol Methods       Date:  2015-02-11       Impact factor: 2.014

3.  Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Authors:  Donald N Forthal; Gary Landucci; Tran B Phan; Juan Becerra
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.

Authors:  Adriano Boasso; Jean-Philippe Herbeuval; Andrew W Hardy; Stephanie A Anderson; Matthew J Dolan; Dietmar Fuchs; Gene M Shearer
Journal:  Blood       Date:  2006-12-07       Impact factor: 22.113

5.  HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity.

Authors:  Nobuyuki Matoba; Adam S Husk; Brian W Barnett; Michelle M Pickel; Charles J Arntzen; David C Montefiori; Atsushi Takahashi; Kazunobu Tanno; Satoshi Omura; Huyen Cao; Jason P Mooney; Carl V Hanson; Haruo Tanaka
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

6.  Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution.

Authors:  Terrence M Dobrowsky; Yan Zhou; Sean X Sun; Robert F Siliciano; Denis Wirtz
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

Review 7.  Advances in Long-Acting Agents for the Treatment of HIV Infection.

Authors:  Aadia I Rana; Jose R Castillo-Mancilla; Karen T Tashima; Raphael L Landovitz
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

8.  Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes.

Authors:  James Swetnam; Evgeny Shmelkov; Susan Zolla-Pazner; Timothy Cardozo
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

9.  HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape.

Authors:  S Abigail Smith; Charles Wood; John T West
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

10.  Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity.

Authors:  Hans Rempel; Cyrus Calosing; Bing Sun; Lynn Pulliam
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.